{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:17:23Z","timestamp":1792811843985,"version":"4.5.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"the korea medical device development fund grant","award":["9991007421, KMDF_PR_20200901_0187"],"award-info":[{"award-number":["9991007421, KMDF_PR_20200901_0187"]}],"id":[{"id":"https:\/\/ror.org\/03g98ap29","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Purpose:<\/jats:title>\n                    <jats:p>This study aimed to evaluate the comparative efficacy and safety of 4 non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians with non-valvular atrial fibrillation in real-world practice through a network meta-analysis of observational studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We searched multiple comprehensive databases (PubMed, Embase, and Cochrane library) for studies published until August 2020. Hazard ratios and 95% confidence intervals were used for the pooled estimates. Efficacy outcomes included ischemic stroke (IS), stroke\/systemic embolism (SSE), myocardial infarction (MI), and all-cause mortality, and safety outcomes included major bleeding, gastrointestinal (GI) bleeding, and intracerebral hemorrhage (ICH). The\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      score was calculated for ranking probabilities. Subgroup analyses were separately performed in accordance with the dosage range of NOACs (\u201cstandard-\u201d and \u201clow-dose\u201d).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 11, 6, and 8 studies were allocated to the total population, standard-dose group, and low-dose group, respectively. In the total study population, edoxaban ranked the best in terms of IS and ICH prevention and apixaban ranked the best for SSE, major bleeding, and GI bleeding. In the standard-dose regimen, apixaban ranked the best in terms of IS and SSE prevention. For major bleeding, GI bleeding, and ICH, edoxaban ranked the best. In the low-dose regimen, edoxaban ranked the best for IS, SSE, GI bleeding, and ICH prevention. For major bleeding prevention, apixaban ranked best.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>All 4 NOACs had different efficacy and safety outcomes according to their type and dosage. Apixaban and edoxaban might be relatively better and more well-balanced treatment for Asian patients with non-valvular atrial fibrillation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000026883","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T16:16:44Z","timestamp":1629130604000},"page":"e26883","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Real-world oral anticoagulants for Asian patients with non-valvular atrial fibrillation"],"prefix":"10.1097","volume":"100","author":[{"given":"Seung Min","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Neurology, Veterans Health Service Medical Center, Seoul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Tae","family":"Jeon","sequence":"additional","affiliation":[{"name":"Department of Neurology, Korea University Ansan Hospital, Korea University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Man","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Neurology, Korea University Ansan Hospital, Korea University College of Medicine"},{"name":"Korea University Zebrafish Translational Medical Research Center, Ansan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Sung","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"R1-20250504","first-page":"789","article-title":"Stroke prevention in atrial fibrillation: an Asian perspective","volume":"111","author":"Chiang","year":"2014","journal-title":"Thromb Haemost"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","article-title":"Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijcard.2011.12.033","article-title":"Atrial fibrillation management in Asia: from the Asian expert forum on atrial fibrillation","volume":"164","author":"Chiang","year":"2013","journal-title":"Int J Cardiol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/CIRCULATIONAHA.111.018820","article-title":"Global variation in the relative burden of stroke and ischemic heart disease","volume":"124","author":"Kim","year":"2011","journal-title":"Circulation"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5853\/jos.2016.00052","article-title":"Asian patients with stroke plus atrial fibrillation and the dose of non-vitamin K oral anticoagulants","volume":"18","author":"Bang","year":"2016","journal-title":"J Stroke"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/heartjnl-2013-303767","article-title":"Ethnicity and stroke risk in patients with atrial fibrillation","volume":"99","author":"Mathur","year":"2013","journal-title":"Heart"},{"key":"R8-20250504","first-page":"e199","article-title":"2014\u200aAHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3988\/jcn.2017.13.3.273","article-title":"Quality of anticoagulation with warfarin in Korean patients with atrial fibrillation and prior stroke: a multicenter retrospective observational study","volume":"13","author":"Hong","year":"2017","journal-title":"J Clin Neurol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijcard.2014.11.182","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal","volume":"180","author":"Lip","year":"2015","journal-title":"Int J Cardiol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s10741-019-09878-y","article-title":"Non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: evidences from the real-world data","volume":"25","author":"Xue","year":"2020","journal-title":"Heart Fail Rev"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1161\/STROKEAHA.119.026054","article-title":"Non-vitamin K antagonist oral anticoagulants versus warfarin in Asians with atrial fibrillation: meta-analysis of randomized trials and real-world studies","volume":"50","author":"Xue","year":"2019","journal-title":"Stroke"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"e21025","DOI":"10.1097\/MD.0000000000021025","article-title":"The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: a PRISMA-compliant article","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1076029619885188","DOI":"10.1177\/1076029619885188","article-title":"Efficacy and safety of non-vitamin K antagonist oral anticoagulants in Asians with nonvalvular atrial fibrillation: a network meta-analysis","volume":"25","author":"Xiong","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12872-019-1165-5","article-title":"Indirect comparison of novel oral anticoagulants among Asians with non-valvular atrial fibrillation in the real world setting: a network meta-analysis","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e001232","DOI":"10.1136\/openhrt-2019-001232","article-title":"Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data","volume":"7","author":"Kohsaka","year":"2020","journal-title":"Open Heart"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1161\/STROKEAHA.119.025536","article-title":"Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation","volume":"50","author":"Lee","year":"2019","journal-title":"Stroke"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chest.2019.04.108","article-title":"Effectiveness and safety of four direct oral anticoagulants in asian patients with nonvalvular atrial fibrillation","volume":"156","author":"Chan","year":"2019","journal-title":"Chest"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"Rucker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/clc.22649","article-title":"Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project","volume":"40","author":"Li","year":"2017","journal-title":"Clin Cardiol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/STROKEAHA.118.023093","article-title":"Outcomes after use of standard- and low-dose non-vitamin K oral anticoagulants in asian patients with atrial fibrillation","volume":"50","author":"Cho","year":"2019","journal-title":"Stroke"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/clc.22069","article-title":"Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong","volume":"35","author":"Ho","year":"2012","journal-title":"Clin Cardiol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.joa.2016.07.007","article-title":"Effectiveness and safety of dabigatran versus warfarin in \u201creal-world\u201d Japanese patients with atrial fibrillation: a single-center observational study","volume":"33","author":"Naganuma","year":"2017","journal-title":"J Arrhythm"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.hrthm.2015.09.015","article-title":"Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation","volume":"13","author":"Chan","year":"2016","journal-title":"Heart Rhythm"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/1076029615584664","article-title":"A comparison of dabigatran with warfarin for stroke prevention in atrial fibrillation in an Asian population","volume":"22","author":"Yap","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4068\/cmj.2019.55.1.54","article-title":"Real world comparison of rivaroxaban and warfarin in korean patients with atrial fibrillation: propensity matching cohort analysis","volume":"55","author":"Jeong","year":"2019","journal-title":"Chonnam Med J"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jacc.2018.05.066","article-title":"Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety","volume":"72","author":"Lee","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/14017431.2019.1594353","article-title":"Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis","volume":"53","author":"Antza","year":"2019","journal-title":"Scand Cardiovasc J"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1253\/circj.CJ-15-1082","article-title":"Edoxaban vs. warfarin in East Asian patients with atrial fibrillation\u2014an ENGAGE AF-TIMI 48 subanalysis","volume":"80","author":"Yamashita","year":"2016","journal-title":"Circ J"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijcard.2016.08.236","article-title":"Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFIELD-AF registry","volume":"223","author":"Oh","year":"2016","journal-title":"Int J Cardiol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"e000067","DOI":"10.1161\/JAHA.112.000067","article-title":"Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial","volume":"2","author":"Singer","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3349\/ymj.2019.60.3.277","article-title":"Label adherence for non-vitamin K antagonist oral anticoagulants in a prospective cohort of asian patients with atrial fibrillation","volume":"60","author":"Lee","year":"2019","journal-title":"Yonsei Med J"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-Label dosing of non-vitamin k antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","article-title":"Non-vitamin k antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction","volume":"69","author":"Yao","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.amjcard.2020.01.044","article-title":"Pattern and impact of off-label underdosing of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing","volume":"125","author":"Cho","year":"2020","journal-title":"Am J Cardiol"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/europace\/eux247","article-title":"Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation","volume":"19","author":"Lee","year":"2017","journal-title":"Europace"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:39:57Z","timestamp":1746322797000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026883"}},"subtitle":["A PRISMA-compliant article"],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":41,"journal-issue":{"issue":"32","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026883","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]},"assertion":[{"value":"2021-01-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}